{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-052107","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.869324+00:00","generated_at":"2026-05-15T01:02:05.004004+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bicycle Therapeutics Q1 2026 net loss $60.8M, restructures, cuts 30% staff","bullets":["Net loss $60.8M ($0.87/sh) flat YoY; collaboration revenue dropped to $0.9M from $10.0M.","Cash $559.5M at March 31, 2026; expects runway into 2030 after cost cuts.","Workforce reduced ~30%; annual operating expenses expected to drop ~50%.","Duravelo-2 (zelenectide) converted to randomized Phase 2; Duravelo-3/4 trials discontinued.","Phase 2 trial of nuzefatide in pancreatic cancer started; first patient dosed April 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-052107","json":"https://secwatch.observer/filing/0001104659-26-052107.json","markdown":"https://secwatch.observer/filing/0001104659-26-052107.md","text":"https://secwatch.observer/filing/0001104659-26-052107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926052107/0001104659-26-052107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926052107/tm2613019d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:02:05.004004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4fde1e4e03a9ddd00f53fbdd0b9c7e7e83f89d02","claim":"BICYCLE THERAPEUTICS PLC reported financial results for the fiscal quarter ended March 31, 2026.","evidence_excerpt":"On April 30, 2026, Bicycle Therapeutics plc issued a press release announcing financial results for the fiscal quarter ended March 31, 2026 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465926052107/0001104659-26-052107-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}